Back to Trial

Oracle Runs

Oracle findings and outcome history for Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors (NCT04609566).

Runs
1
Findings
1
Latest Run
Apr 1, 2026, 7:05 PM
Resolution Evidence
Outcome
YES
Status
Resolved
Settlement Date
4/1/26 UTC
Executive Summary

Public sources for NCT04609566 frame this Phase 2 study positively. The sponsor said the combination data were "intriguing" and supported continued research, and the later peer-reviewed paper concluded the trial showed clinically meaningful, durable responses with encouraging survival, supporting activity of the regimen.

Sources
Sponsorbusinesswire.com11/3/23
Seagen Highlights First Solid Tumor Data for an ADCETRIS Immunotherapy Combination at SITC

Sponsor described initial Phase 2 NCT04609566 data as intriguing and said the ADCETRIS+pembrolizumab combination supported continued research; safety was consistent with prior studies.

View source
Web Searchpmc.ncbi.nlm.nih.gov1/7/25
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic NSCLC and Melanoma

Peer-reviewed report for SGN35-033/NCT04609566 concluded the regimen produced clinically meaningful, durable responses with encouraging OS/PFS, supporting activity in anti–PD-1-refractory solid tumors.

View source
All Oracle Findings

Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.

YESAccepted90% confidenceGPT-5.4 (OpenAI)

Will the results be positive?

Public sources for NCT04609566 frame this Phase 2 study positively. The sponsor said the combination data were "intriguing" and supported continued research, and the later peer-reviewed paper concluded the trial showed clinically meaningful, durable responses with encouraging survival, supporting activity of the regimen.

Found Apr 1, 2026, 7:05 PMOutcome date Nov 3, 2023, 12:00 AMReviewed Apr 1, 2026, 7:16 PM
Sponsorbusinesswire.comNov 3, 2023, 12:00 AM
Seagen Highlights First Solid Tumor Data for an ADCETRIS Immunotherapy Combination at SITC
Sponsor described initial Phase 2 NCT04609566 data as intriguing and said the ADCETRIS+pembrolizumab combination supported continued research; safety was consistent with prior studies.
Web Searchpmc.ncbi.nlm.nih.govJan 7, 2025, 12:00 AM
Phase II Open-Label Trial of Brentuximab Vedotin with Pembrolizumab in PD-1–Pretreated Metastatic NSCLC and Melanoma
Peer-reviewed report for SGN35-033/NCT04609566 concluded the regimen produced clinically meaningful, durable responses with encouraging OS/PFS, supporting activity in anti–PD-1-refractory solid tumors.
Outcome History

Public history of accepted oracle reviews and recorded outcome changes for this trial.

Accepted Oracle Review (Legacy)Apr 1, 2026, 7:16 PM

Will the results be positive?

PendingtoYEScurrentYES
GPT-5.4 (OpenAI)90% confidenceReviewed Apr 1, 2026, 7:16 PM

Public sources for NCT04609566 frame this Phase 2 study positively. The sponsor said the combination data were "intriguing" and supported continued research, and the later peer-reviewed paper concluded the trial showed clinically meaningful, durable responses with encouraging survival, supporting activity of the regimen.